

National Innovative Medicines Fund List

(Including live list of indications funded via the Innovative Medicines Fund with their commissioning criteria for use)

v1.15

19-Aug-25

National Innovative Medicines Fund (IMF) List

A. National IMF List

Notes: This list should be read in conjunction with all other available information found at: <https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/>

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
ETR1a_v1.0	Etranacogene dezaparvovec	ETR1a- Initial Funding Application for treating moderately severe or severe haemophilia B (TA989) where the following criteria have been met:	1. The prescribing clinician confirms the patient is aged 18 years or older. 2. The prescribing clinician confirms the patient has moderately severe or severe haemophilia B 3. The prescribing clinician confirms the patient has a demonstrated absence of Factor IX inhibitors and no previous history of Factor IX inhibitors. 4. The prescribing clinician confirms a pre-existing neutralising antibody titre has been performed and that the patient does not have neutralising anti-AAV5 antibodies above a titre of 1:678 (7-point assay) or 1:898 (9-point assay). 5. The prescribing clinician confirms the patient’s baseline hepatic function has been assessed. 6. The prescribing clinician confirms compliance with UKHCDO guideline, in particular the approval and pathway process and that treatment will be delivered by a commissioned haemophilia ATMP treatment hub. 7. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA989.	From 27-June-24		N/A	N/A	Yes	nca
ETR1b_v1.0	Etranacogene dezaparvovec	ETR1b-Post Infusion Funding Application for treating moderately severe or severe haemophilia B (TA989) where the following criteria have been met:	1.The prescribing clinician confirms that one of the following applies: -The patient remained eligible for treatment and was infused with etranacogene dezaparvovec -The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product -The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product -The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected) -The product was destroyed following identification of other damage to the product Please enter the date of infusion with etranacogene dezaparvovec if option 1 applies, otherwise please enter '00/00/0000': _____ 2. The prescribing clinician confirms that etranacogene dezaparvovec was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA989						

National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
EXA1a_v1.0	Exagamlogene autotemcel	EXA1a-Initial Funding Application (for each cell collection) – Exagamlogene autotemcel for treating transfusion-dependent beta-thalassaemia [TA1003] where the following criteria have been met:	1.The prescribing clinician confirms that one of the following applies: a. The prescribing clinician confirms the patient is 16 years and older, being treated in an adult service, and the centre is commissioned to deliver this treatment OR b. The prescribing clinician confirms the patient is 12-18 years old at the point of referral to the panel for approval, is being treated within a paediatric service, and the centre is commissioned to deliver treatment in this age group 2. The prescribing clinician confirms the patient has transfusion-dependent beta-thalassaemia (diagnosis confirmed by DNA technology) and is suitable for haematopoietic stem cell transplant but a human leukocyte antigen (HLA)- matched related haematopoietic stem cell donor is not available. 3. The prescribing clinician confirms that the patient has not received a prior allogeneic or autologous haematopoietic stem cell transplant. 4. The prescribing clinician confirms that approval for treatment has been obtained from the National Haemoglobinopathy Panel on: To enter date in the box as (00/00/0000) ----- 5. The prescribing clinician confirms that one of the following applies 5a.The prescribing clinician confirms this is the patients first mobilisation cycle* OR 5b. The prescribing clinician confirms this is the patients second mobilisation cycle* OR 5c. The prescribing clinician confirms this is the patients third mobilisation cycle* OR 5d. The prescribing clinician confirms this is the patients fourth mobilisation cycle* OR 5e. The prescribing clinician confirms this is the patients fifth mobilisation cycle* *One mobilisation cycle is defined as mobilisation plus the completion of all collective attempts at apheresis that may occur from Day 5 to Day 7 (inclusive). 6. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA1003 . 7. The prescribing clinician confirms the required data will be collected as per the managed access agreement.	From 08-August-24		N/A	N/A	Yes	nca
EXA1b_v1.0	Exagamlogene autotemcel	EXA1b-Funding Application (treatment outcome)– Exagamlogene autotemcel for treating transfusion-dependent beta-thalassaemia [TA1003] where the following criteria have been met:	1. The prescribing clinician confirms that one of the following applies: The patient remained eligible for treatment and was infused with exagamlogene autotemcel. The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product. The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product. The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected). The product was destroyed following identification of other damage to the product The product was destroyed following identification of other damage to the product SmPC and the managed access agreement as detailed in NICE TA 1003 and please enter the date of infusion with Exagamlogene autotemcel, otherwise please enter '00/00/0000':	From 08-August-24		N/A	N/A	Yes	nca

National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
EXA2a_v1.0	Exagamlogene autotemcel	EXA2a-National Innovative Medicines Fund Application Form – Initial Funding Application (for each cell collection) – Exagamlogene autotemcel for treating sickle cell disease [ID4016] where the following criteria have been met:	1. To note, a separate Blueteq form should be submitted for use of plerixafor 1a. The prescribing clinician confirms the patient is 16 years and older, being treated in an adult service, and the centre is commissioned to deliver this treatment OR 1b. The prescribing clinician confirms the patient is 12-18 years old at the point of referral to the panel for approval, is being treated within a paediatric service, and the centre is commissioned to deliver treatment in this age group. 2.The prescribing clinician confirms the patient has sickle cell disease and has recurrent vaso-occlusive crises (VOCs) defined as at least 2 VOC's per year during the 2 previous years. To note: In the SmPC: Patients were eligible for the study if they had a history of at least 2 severe vaso-occlusive crisis events per year in the 2 years prior to screening, which were defined as: •an acute pain event •acute chest syndrome •priapism lasting at least 27hours •splenic sequestration 3. The prescribing clinician confirms the patient has: a. $\beta S/\beta S$, $\beta S/\beta +$ or $\beta S/\beta 0$ genotype, b. is suitable for haematopoietic stem cell transplant, c. and for whom a human leukocyte antigen (HLA)-matched related haematopoietic stem cell donor is not available. 5. The prescribing clinician confirms that approval for treatment has been obtained from the National Haemoglobinopathy Panel on: To enter date in the box as (00/00/0000) 5a.The prescribing clinician confirms this is the patients first mobilisation cycle* OR 5b. The prescribing clinician confirms this is the patients second mobilisation cycle* OR 5c. The prescribing clinician confirms this is the patients third mobilisation cycle* OR 5d. The prescribing clinician confirms this is the patients fourth mobilisation cycle* OR 5e. The prescribing clinician confirms this is the patients fifth mobilisation cycle* OR 5f. The prescribing clinician confirms this is the patients sixth mobilisation cycle* * One mobilisation cycle is defined as mobilisation plus the completion of all collective attempts at apheresis that occur from Day 1 to Day 3 (inclusive) 6. The prescribing clinician confirms that use is in accordance with the SmPC and the managed access agreement, as detailed in NICE TA ID4016 7. The prescribing clinician confirms the required data will be collected as per the managed access agreement	From 31-January-25	N/A	N/A	Yes	nca	
EXA2b_v1.0	Exagamlogene autotemcel	EXA2b-National Innovative Medicines Fund Application Form – Funding Application (treatment outcome) – Exagamlogene autotemcel for treating sickle cell disease [ID4016] where the following criteria have been met:	1. The prescribing clinician confirms that one of the following applies: a. The patient remained eligible for treatment and was infused with exagamlogene autotemcel. b. The patient was no longer eligible for treatment and the order was cancelled before acceptance of the product. c. The patient was no longer eligible for treatment and the order had to be cancelled after acceptance of the product. d. The product was destroyed following identification of a defect or latent defect (i.e. a fault occurring prior to receipt of product, regardless of when it was detected). e. The product was destroyed following identification of other damage to the product 2. If option 1a applies, the prescribing clinician confirmsthat Exagamlogene autotemcel was otherwise used as set out in the SmPC and the managed access agreement as detailed in NICE TA ID4016 and please enter the date of infusion with Exagamlogene autotemcel, otherwise please enter '00/00/0000':	From 31-January-25	N/A	N/A	Yes	nca	

National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
MAR1_v1.0	Marstacimab	MAR1_v1.0 – National Innovative Medicines Fund Application Form – Marstacimab for treating severe haemophilia B in people 12 years and over without anti-factor antibodies [ID 6342]	1. The prescribing clinician confirms the patient is aged 12 years and over.	From 23-June-25		Yes	Agreed	No	22-Sep-25
			2.The prescribing clinician confirms the patient has severe haemophilia B (a factor IX activity level of less than 1%).						
			3.The prescribing clinician confirms the patient does not have factor 9 inhibitors (anti-factor antibodies)						
			4. The prescribing clinician confirms the patient weighs at least 35kg.						
			5. The prescribing clinician confirms that the patient will receive the licensed dose and frequency of marstacimab in line with its marketing authorisation (Summary of Product Characteristics).						
			6. The prescribing clinician confirms that the patient/carer has been trained in the storage, handling and administration of their marstacimab in regimen, and that the clinical team is satisfied of their competence in these respects.						
			7. The prescribing clinician confirms that the patient/carer has been advised that it is a requirement to provide the clinical team with data pertaining to dose administration and related clinical sequelae such as bleeding episodes. This is most easily achieved through the use of a secure therapy recording digital interface, such as Haemtrack™ (prior patient registration required).						

National Innovative Medicines Fund (IMF) List

Blueteq Form ref:	Drug	Indication	Criteria for use	Available to new patients		Eligible for Interim Funding	Interim Funding agreed by manufacturer	IMF Managed Access Scheme	Expected Entry into Baseline Commissioning (if known)
				Yes	Yes (but notice of removal served)				
BENR1_v1.0	Benralizumab	BENR1_v1.0 – National Innovative Medicines Fund Application Form – Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [NICE ID6266]	1.The prescribing clinician confirms that the patient has relapsing or refractory eosinophilic granulomatosis with polyangiitis 2.The prescribing clinician confirms the patient is aged 18 years or over 3. The prescribing clinician confirms that benralizumab will be used as an add-on to standard care (oral corticosteroids with or without immunosuppressants) within its marketing authorisation. 4. The prescribing clinician confirms that benralizumab will be stopped after 52 weeks if the EGPA has not responded, with response defined as: a Birmingham Vasculitis Activity Score (BVAS) score of 0, and a reduction in oral corticosteroid use, either: by 50% or more since starting benralizumab, or to 7.5 mg or less per day. 5. The prescribing clinician confirms that a decision to continue benralizumab will be made at least annually based on disease severity, level of disease control and blood eosinophil counts 6. The prescribing clinician confirms that this patient has been discussed with a relevant specialist MDT and it has been agreed that benralizumab is the most appropriate therapy 7. The prescribing clinician confirms the licensed dose and frequency of 30 mg by subcutaneous injection every 4 weeks.will be used.	From 14-Aug-25		Yes	Agreed	No	02-Dec-25

National Innovative Medicines Fund (IMF) List

B. IMF drug moved into routine commissioning

	IMF drug moved into routine commissioning					
	Form code	Drug name	Indication	Form code	Start date of IMF fund	Date of routine commissioning
	BUL1_v1.0	Bulevirtide	Bulevirtide for treating chronic hepatitis D (NICE TA896)	BUL1_v1.0	07/06/2023	05/09/2023
	SEC1_v1.0	Secukinumab	Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)	SEC1_v1.0	27/10/2023	06/03/2024
	SEB1_v1.0	Sebelipase alfa	Sebelipase alfa for treating Wolman disease (HST30)	SEB1_v1.0	27/11/2023	09/04/2024
	BEL1_v1.0	Belumosudil	Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)	BEL1_v1.0	21/12/2023	07/05/2024
	VOX1a_v1.0	Voxelotor	Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)	VOX1a_v1.0	03/05/2024	12/07/2024
	IP11_v1.0	Iptacopan	Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)	IP11_v1.0	04/09/2024	03/12/2024
	ELAF1_v1.0	Elafibranor	Elafibranor for treating primary biliary cholangitis (TA1016)	ELAF1_v1.0	22/10/2024	12/02/2025
	TAF1a_v1.0	Tafamidis	Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)	TAF1a_v1.0	13/05/2024	19/07/2024
	CRO1_v1.0	Crovalimab	Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)	CRO1_v1.0	20/11/2024	20/12/2024
	UBL1_v1.0	Ublituximab	Ublituximab for treating relapsing multiple sclerosis (TA1025)	UBL1_v1.0	29/11/2024	17/01/2025
	FEN1_v1.0	Fenfluramine	Fenfluramine for treating seizures associated with Lennox-Gastaut syndrome in people 2 years and over (TA1050)	FEN1_v1.0	20/02/2025	24/06/2025
	STS1_v1.0	Sodium thiosulfate	Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours (TA1034)	STS1_v1.0	26/02/2025	22/04/2025
	RUX3_v1.0	Ruxolitinib	Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)	RUX3_v1.0	21/03/2025	14/07/2025
	LEN1_v1.0	Leniolisib	Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over (HST33)	LEN1_v1.0	13/03/2025	22/07/2025

National Innovative Medicines Fund (IMF) List

Version Control			
Version No.	Date published	Author(s)	Revision summary
0.1	n/a	D Dwyer	Initial draft of new IMF list, based on pre-existing national IMF list but updated for changes to the IMF, for review.
1.0	03/07/2024	S Patel; R Gowa; P Ryan; S Ahmed	Final version of new IMF list
1.1	19/08/2024	R Gowa; S Ahmed	1 drug/indication recommended for the IMF, 2 drugs/indications removed from the list
1.2	06/09/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.3	22/10/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.4	20/11/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.5	06/12/2024	R Gowa; S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 1 drugs/indications removed from the list
1.6	20/12/2024	R Gowa; S Ahmed	0 drug/indication recommended for the IMF
1.7	23/12/2024	R Gowa; S Ahmed	1 drugs/indications removed from the list
1.8	31/01/2025	R Gowa; S Ahmed	1 drug/indication recommended for the IMF, 1 drugs/indications removed from the list
1.9	20/02/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.10	27/02/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.11	21/03/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.12	27/03/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding
1.13	24/06/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding, 2 drugs/indications removed from the list
1.14	16/07/2025	S Mcaleer;S Ahmed	2 drugs/indications removed from the list, Added List : B. IMF drug moved into routine commissioning
1.15	14/08/2025	S Mcaleer;S Ahmed	1 drug/indication recommended for routine commissioning, receiving IMF interim funding

National Innovative Medicines Fund (IMF) List

Changes to recent versions	
General or criteria changed	Summary of changes
Changes to version 1.0	
ETR1a_v1.0, ETR1b_v1.0	Recommended for the IMF
VOX1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
TAF1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.1	
EXA1a_v1.0, EXA1b_v1.0	Recommended for the IMF
VOX1a_v1.0, TAF1a_v1.0	Removed from the list
Changes to version 1.2	
IPT1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.3	
ELAF1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
EXA1a_v1.0, EXA1b_v1.0	Updated EXA1a questions Q4 & Q5; EXA1b Question 2&3 combined
Changes to version 1.4	
CRO1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
ETR1a_v1.0, ETR1b_v1.0, EXA1a_v1.0, EXA1b_v1.0, ELAF1_v1.0 and IPT1_v1.0	Updated IDs
Changes to version 1.5	
UBL1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
IPT1_v1.0	Removed from the list
Changes to version 1.6	
CRO1_v1.1	Updated CRO1 question 2 & added a new question.
Changes to version 1.7	
CRO1_v1.1	Removed from the list
Changes to version 1.8	
EXA2a_v1.0, EXA2b_v1.0	Recommended for the IMF
UBL1_v1.0	Removed from the list
Changes to version 1.9	
FEN1a_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.10	
STS1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
ELAF1_v1.0	1 drugs/indications removed from the list
Changes to version 1.11	
LEN11a_v1.0 and LEN11b_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.12	
RUX3_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.13	
MAR1_v1.0	Recommended for routine commissioning, receiving IMF interim funding
Changes to version 1.14	
RUX3_v1.0	Removed from the list
LEN11a_v1.0 and LEN11b_v1.0	Removed from the list
Changes to version 1.15	
BENR1_v1.0	Recommended for routine commissioning, receiving IMF interim funding